

Charity registration number: 1164238

Action Kidney Cancer

Annual Report and Financial Statements

for the Year Ended 31 October 2024

Action Kidney Cancer

Contents (continued)

Reference and Administrative Details	1
Trustees' Report	2 to 7
Statement of Trustees' Responsibilities	8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Notes to the Financial Statements	12 to 19

Action Kidney Cancer

Reference and Administrative Details

Chairman	A Thomas
Trustees	A Thomas J Larkin J Pym A Fielding S Turajlic
Charity Registration Number	1164238
Principal Office	11th Floor 3 Piccadilly Manchester M1 3BN
Independent Examiner	Stockdale Accountants Ltd St Ingungger Offices Lanivet Bodmin Cornwall PL30 5HS

Annual Trustee Report

Action Kidney Cancer For the Year Ending 31st October 2024

ACTION KIDNEY CANCER (Action Kidney Cancer is the working name of 'Kidney Cancer Support Network')

The Trustees present their report together with the financial statement for the year ended 31st October 2024.

The financial statements comply with current statutory requirements, the Charity's governing document, and the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (SORP FRS 102) (edition October 2019, effective January 2019), and the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102).

Registered charity number: 1164238 in England Wales, SC051330 in Scotland

Status: Charitable Incorporated Organisation (CIO) Incorporated 3 November 2015 England Wales

Status: Charitable Incorporated organisation (CIO) incorporated 7 October 2021 Scotland

Principal and registered address:

ACTION KIDNEY CANCER
Kidney Cancer Support Network,
11th Floor, 3 Piccadilly Place
Manchester M1 3BN

Trustees

Mr Andy Thomas – Chair
Professor James Larkin
Mr Jonathan Pym
Professor Samra Turajlic
Ms. Alison Fielding
Mrs Salena Mulhere

Structure, governance, and management.

ACTION KIDNEY CANCER began its work as a voluntary support organisation in 2006. As the Groups responsibilities, grew it was registered as a formal charitable incorporated organisation (CIO) on the 3rd November 2015. The charity is managed according to its governing documents dated 3rd November 2015. The charity underwent a complete rebranding during in 2021 and is now known by its working name ACTION KIDNEY CANCER.

Where there is a requirement for new Trustees, they will be identified and appointed by the current Trustees. The ACTION KIDNEY CANCER management team is responsible for the induction of any new Trustees, and this will involve a briefing about Trustee responsibilities, the governing document, and the

adopted operating policies and procedures of the charity. All Trustees provide their services to the charity on a voluntary unpaid basis.

The Trustees delegate day-to-day responsibility for the running of the charity to the Executive Officer and the management team who are accountable to the Trustees and report to the Trustees throughout the year as required and at regular Trustee meetings.

The Trustees have a duty to identify and review all risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Trustees regularly review the risks that the charity may face, and the Trustees will continue to monitor the risks associated with its activities and continue to be vigilant as to other risks that might be associated with a charity providing support services to people affected by kidney cancer.

The Trustees have agreed and adopted a series of operating policies to ensure the charity runs smoothly and complies with all charity commission requirements and legal responsibilities. The operating policies are reviewed every two years and are available by written request to the ACTION KIDNEY CANCER management team. Some policies are available via the ACTION KIDNEY CANCER website.

The Trustees declare as part of this annual return, that there are no serious incidents or other matters the Trustees should have reported to the Charity Commission.

Charity objectives and activities

To promote and protect the physical and mental health of patients with kidney cancer in the United Kingdom by:

1. The provision of information, support, education and practical advice to kidney cancer patients, their families, and their carers
2. To advance the education and awareness of all matters relating to kidney cancer with the general public
3. Promoting and supporting research projects into the causes, diagnosis, prevention, treatment, and cure of kidney cancer and disseminating the results of such research.

The Trustees meet a minimum of once a year, to discuss, agree and record charitable activities, strategy, funding priorities, and operating policies, including risk management. Project meetings are held throughout the year as required and/or as requested by the Trustees or management team.

Public benefit

The Trustees confirm that they have referred to the guidance provided by the charity commission's general guidance and advice on public benefit. In planning all activities including financial policies, the trustees confirm they have complied with the duty in section 17(5) of the 2011 Charities Act and the Trustees are satisfied that all charitable activities during the year are for the benefit of the public.

Chair's Statement

This year has been one of both consolidation and progress for Action Kidney Cancer. Despite sector-wide funding challenges, our small team has worked tirelessly to ensure that kidney cancer patients and their carers receive the support, advocacy, and guidance they need. I am proud of what we have achieved and deeply grateful to every member of the management team who have worked so hard to make these achievements possible.

About Action Kidney Cancer

Action Kidney Cancer is the **UK's only patient founded and patient -led kidney cancer charity**, founded in 2006 and formally registered in 2015. We exist to ensure that all kidney cancer patients have access to the best possible care and treatment. We work to improve outcomes and the quality of life for kidney cancer patients, survivors, carers, and their families.

Our charity is guided by a unique Board of Trustees that includes world-leading clinicians – **Professor James Larkin (Royal Marsden)** and **Professor Samra Turajlic (Francis Crick Institute/Royal Marsden)** – and Mr Andy Thomas, Mr Jon Pym, Mrs Alison Fielding BEM, and Mrs Salene Mulhere who are patients and carers with personal experience of kidney cancer. This ensures our charity is guided by people who have a shared goal to serve the kidney cancer community and to ensure the charity remains **authentic, practical, and patient-centred**.

We provide:

- Personalised, practical support for patients and carers navigating the complexities of the NHS
 - High-quality, evidence-based patient information and resources in a variety of formats
 - Advocacy on policy, treatment access and research
 - Daily updates on news and advances through social media and our website
 - Tailored support and resources that reflect the diverse cultural, ethnic, and socioeconomic backgrounds of people affected by kidney cancer.
-

Main Achievements This Year

Patient Support

This year we have strengthened and expanded our support services to ensure patients and carers receive help when they need it most:

- Our **online support forum** saw a significant increase in engagement and new members.
- Our **dedicated helpline** continued to provide compassionate one-to-one support.
- We increased our **“Ask the Expert” videos** to 21 in our online library.
- **New patient information resources** in patient friendly formats were added to our website, tailored to UK-specific needs.
- Our team presented at a **support meeting in Oxford** and supported the launch of a **new group in Surrey**.
- We successfully launched the **Renal Oncology Nurse Network** supporting CNSs across the Country; hosting patient information days, distributing resources and opening new lines of communication.
- We partnered with **Project Flutter** to create a launch video and supported their efforts to distribute **butterfly bags and cushions** to NHS hospitals.
- We authored two of four modules for the **RCC4Nurses** online course.

- We led the **Coalition for Reducing Bureaucracy in clinical trials** working group developing a patient-friendly ICF (Informed Consent Form) template.
 - We participated in several **Health Technology Assessment (HTA)** submissions.
-

Research Support & Involvement

We have continued to influence and support kidney cancer research through strong patient & public involvement:

- **UK Renal Oncology Group:** We provide a full secretariat support for this newly formed group of renal clinicians focused on non-commercial research priorities following the demise of the NCRI.
 - Responsibility for promoting the International Kidney Cancer Coalition **Global Patient Survey**, achieving **197 UK responses**—one of the highest response rates.
 - We manage the Patient Involvement and Public engagement for the Global **CARE-1 Clinical trial**, a large cross border European biomarker study, including establishing an **International Patient Advisory Board**.
 - Promoted **PPIE best practice** and supported funding applications across the UK.
 - Participated in:
 - **NICE RCC Guidelines Committee**
 - **North West Cancer Research (NWCR)** - Immunotherapy Project Steering Committee
 - Trial Management Group for **REFINE clinical Trial**
 - Patient member of **Trial management group** for an International consensus paper on Core Outcomes for RCC
 - Membership of the campaign **Reducing Bureaucracy in Clinical Trials**
 - Celebrated the publication of the **OPTIC abstract and research paper** (Oct 2024).
-

Policy and Advocacy

We have maintained a strong presence in national and regional advocacy:

- **Welsh Cancer Alliance:** Collaborating with 20+ organisations to influence cancer care in Wales.
- **Scottish Cancer Coalition:** Working together to ensure people affected by cancer in Scotland receive the best possible support and treatment.
- **Cancer52:** Representing rare and less common cancers; led the **Access to Clinical Trials Working Group** and participated in the **BIG Cancer52 Conversation 2024**.
- **WECAN Academy:** Presented on patient-led advocacy at this leading European training initiative for advocates.
- **National Kidney Cancer Audit:** Provided patient representation for quarterly reports and the **State of the Nation Report (Sept 2024)**.
- Supported **One Cancer Voice**, a joint call from 60+ charities for a **national cancer strategy** in summer 2024.

- Continued our campaign for **treatment breaks** for patients receiving TKIs and immunotherapy.
-

Awareness & Education

Awareness-raising continues to be an important element of our work

- Supported and promoted **World Kidney Cancer Day (WKCD) 2024**, launching a dedicated webpage and coordinated with several NHS hospitals and research institutions.
 - Partnered with organisations such as **IKCC**, **FROG**, the **Welsh Cancer Alliance**, and the **Scottish Cancer Coalition**.
 - Presented at various pharmaceutical companies to improve understanding of kidney cancer.
 - Hosted a **patient information stand at The Christie Hospital**.
 - Presented at the **IKCC Global Kidney Cancer Summit (South Korea)** on the emotional challenges of diagnosis and communication.
-

Financial Overview

Like many in the UK charity sector, and wider across Europe and North America, we experienced reduced funding from pharmaceutical companies in 2024. This trend is echoed across health related charities in many Countries and highlights the need for **diversification** of income.

To that end:

- We strengthened **advocacy and research partnerships**
- Our **reserve funds** are now held in **interest-bearing accounts**
- We delivered successful fundraising campaigns, including:
 - **Annual Northern Soul fundraiser**
 - **Annual Golf days**
 - **Sponsored walks and skydives**
 - **School-led event**
 - **London Memorial concert**
 - Our popular **“Gift a Heart”** campaign continues

We are deeply grateful to every volunteer, donor and supporter who makes our work possible.

Looking Ahead

Our priorities for the year ahead include:

- Building sustainable, **diversified income** sources
- Continuing to **grow our patient, carer and family support network**

- Increase our partnership working with **research institutions to provide patient and public involvement**
- Advocating for **better access to care and trials** across the UK.

As we move forward into 2025, we remain steadfast in our belief that no one affected by kidney cancer, whether they are patients, carers, or family members, —should ever feel they have to face kidney cancer alone.

Action Kidney Cancer

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity on 30th June 2025 and signed on its behalf by:



A Thomas
Chairman and trustee

Action Kidney Cancer

Independent Examiner's Report to the trustees of Action Kidney Cancer

I report to the trustees on my examination of the accounts of Action Kidney Cancer for the year ended 31 October 2024.

Responsibilities and basis of report

As the charity trustees of Action Kidney Cancer you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').


I report in respect of my examination of the Action Kidney Cancer's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of Action Kidney Cancer as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.


.....
Hayley Hall
FMAAT

St Ingungger Offices
Lanivet
Bodmin
Cornwall
PL30 5HS

Date: 18/07/25
.....

Action Kidney Cancer

Statement of Financial Activities for the Year Ended 31 October 2024

	Note	Unrestricted funds £	Restricted funds £	Total 2024 £
Income and Endowments from:				
Donations and legacies		46,610	36,210	82,820
Investment income	3	65	-	65
Other income		32,656	-	32,656
Total income		79,331	36,210	115,541
Expenditure on:				
Charitable activities		(91,880)	(20,953)	(112,833)
Total expenditure		(91,880)	(20,953)	(112,833)
Net (expenditure)/income		(12,549)	15,257	2,708
Net movement in funds		(12,549)	15,257	2,708
Reconciliation of funds				
Total funds brought forward		288,824	-	288,824
Total funds carried forward	11	276,275	15,257	291,532
	Note	Unrestricted funds £	Total 2023 £	
Income and Endowments from:				
Donations and legacies			104,633	104,633
Other income			30,064	30,064
Total income			134,697	134,697
Expenditure on:				
Charitable activities			(100,582)	(100,582)
Total expenditure			(100,582)	(100,582)
Net income			34,115	34,115
Net movement in funds			34,115	34,115
Reconciliation of funds				
Total funds brought forward			254,709	254,709
Total funds carried forward	11		288,824	288,824

All of the charity's activities derive from continuing operations during the above two periods.
The funds breakdown for 2023 is shown in note 11.

Action Kidney Cancer

(Registration number: 1164238)
Balance Sheet as at 31 October 2024

	Note	2024 £	2023 £
Current assets			
Debtors	8	9,107	20,645
Cash at bank and in hand	9	<u>290,122</u>	<u>275,489</u>
		299,229	296,134
Creditors: Amounts falling due within one year	10	<u>(7,697)</u>	<u>(7,310)</u>
Net assets		<u>291,532</u>	<u>288,824</u>
Funds of the charity:			
Restricted income funds			
Restricted funds		15,257	-
Unrestricted income funds			
Unrestricted funds		<u>276,275</u>	<u>288,824</u>
Total funds	11	<u>291,532</u>	<u>288,824</u>

The financial statements on pages 10 to 19 were approved by the trustees, and authorised for issue on 30th June 2025 and signed on their behalf by:



A Thomas
Chairman and trustee

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2024

1 Accounting policies

Statement of compliance

The financial statements have been prepared in accordance with the second edition of the Charities Statement of Recommended Practice issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

Basis of preparation

Action Kidney Cancer meets the definition of a public benefit entity under FRS 102. The accounts (financial statements) have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured.

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Investment income

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2024 (continued)

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2024 (continued)

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Statement of Financial Activities over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the charity has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2024 (continued)

Debt instruments

Debt instruments which meet the following conditions are subsequently measured at amortised cost using the effective interest method:

(a) The contractual return to the holder is (i) a fixed amount; (ii) a positive fixed rate or a positive variable rate; or (iii) a combination of a positive or a negative fixed rate and a positive variable rate.

(b) The contract may provide for repayments of the principal or the return to the holder (but not both) to be linked to a single relevant observable index of general price inflation of the currency in which the debt instrument is denominated, provided such links are not leveraged.

(c) The contract may provide for a determinable variation of the return to the holder during the life of the instrument, provided that (i) the new rate satisfies condition (a) and the variation is not contingent on future events other than (1) a change of a contractual variable rate; (2) to protect the holder against credit deterioration of the issuer; (3) changes in levies applied by a central bank or arising from changes in relevant taxation or law; or (ii) the new rate is a market rate of interest and satisfies condition (a).

(d) There is no contractual provision that could, by its terms, result in the holder losing the principal amount or any interest attributable to the current period or prior periods.

(e) Contractual provisions that permit the issuer to prepay a debt instrument or permit the holder to put it back to the issuer before maturity are not contingent on future events, other than to protect the holder against the credit deterioration of the issuer or a change in control of the issuer, or to protect the holder or issuer against changes in levies applied by a central bank or arising from changes in relevant taxation or law.

(f) Contractual provisions may permit the extension of the term of the debt instrument, provided that the return to the holder and any other contractual provisions applicable during the extended term satisfy the conditions of paragraphs (a) to (c).

Debt instruments that are classified as payable or receivable within one year on initial recognition and which meet the above conditions are measured at the undiscounted amount of the cash or other consideration expected to be paid or received, net of impairment.

With the exception of some hedging instruments, other debt instruments not meeting these conditions are measured at fair value through profit or loss.

Commitments to make and receive loans which meet the conditions mentioned above are measured at cost (which may be nil) less impairment.

Investments

Investments in non-convertible preference shares and non-puttable ordinary or preference shares (where shares are publicly traded or their fair value is reliably measurable) are measured at fair value through profit or loss. Where fair value cannot be measured reliably, investments are measured at cost less impairment.

Investments in subsidiaries and associates are measured at cost less impairment. For investments in subsidiaries acquired for consideration including the issue of shares qualifying for merger relief, cost is measured by reference to the nominal value of the shares issued plus fair value of other consideration. Any premium is ignored.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2024 (continued)

Derivative financial instruments

The charity uses derivative financial instruments to reduce exposure to foreign exchange risk and interest rate movements. The charity does not hold or issue derivative financial instruments for speculative purposes.

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. The resulting gain or loss is recognised in statement of financial activities immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in statement of financial activities depends on the nature of the hedge relationship.

Fair value measurement

The best evidence of fair value is a quoted price for an identical asset in an active market. When quoted prices are unavailable, the price of a recent transaction for an identical asset provides evidence of fair value as long as there has not been a significant change in economic circumstances or a significant lapse of time since the transaction took place. If the market is not active and recent transactions of an identical asset on their own are not a good estimate of fair value, the fair value is estimated by using a valuation technique.

2 Income from donations and legacies

	Unrestricted funds General £	Restricted funds £	Total funds £
Donations and legacies;			
Donations from individuals	41,610	-	41,610
Grants, including capital grants;			
Grants from other charities	5,000	36,210	41,210
Total for 2024	<u>46,610</u>	<u>36,210</u>	<u>82,820</u>
Total for 2023	<u>104,633</u>	<u>-</u>	<u>104,633</u>

3 Investment income

	Unrestricted funds General £	Total funds £
Interest receivable and similar income;		
Interest receivable on bank deposits	65	65
Total for 2024	<u>65</u>	<u>65</u>

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2024 (continued)

4 Other income

	Unrestricted funds General £	Total funds £
Advocacy Fees	32,656	32,656
Total for 2024	<u>32,656</u>	<u>32,656</u>
Total for 2023	<u>30,064</u>	<u>30,064</u>

5 Expenditure on charitable activities

	Unrestricted funds General £	Restricted funds £	Total funds £
Note			
support of kidney cancer patients	91,881	20,953	112,834
Governance costs	(1)	-	(1)
Total for 2024	<u>91,880</u>	<u>20,953</u>	<u>112,833</u>
Total for 2023	<u>100,582</u>	<u>-</u>	<u>100,582</u>

6 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any reimbursed expenses or any other benefits from the charity during the year.

7 Taxation

The charity is a registered charity and is therefore exempt from taxation.

8 Debtors

	2024 £	2023 £
Trade debtors	4,441	400
Prepayments	4,666	20,245
	<u>9,107</u>	<u>20,645</u>

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2024 (continued)

9 Cash and cash equivalents

	2024 £	2023 £
Cash at bank	<u>290,122</u>	<u>275,489</u>

10 Creditors: amounts falling due within one year

	2024 £	2023 £
Trade creditors	7,597	7,210
Accruals	<u>100</u>	<u>100</u>
	<u>7,697</u>	<u>7,310</u>

11 Funds

	Balance at 1 November 2023 £	Incoming resources £	Resources expended £	Balance at 31 October 2024 £
Unrestricted				
General	288,824	79,331	(91,880)	276,275
Restricted	<u>-</u>	<u>(36,210)</u>	<u>20,953</u>	<u>(15,257)</u>
Total funds	<u>(288,824)</u>	<u>(115,541)</u>	<u>112,833</u>	<u>(291,532)</u>
	Balance at 1 November 2022 £	Incoming resources £	Resources expended £	Balance at 31 October 2023 £
Unrestricted				
General	<u>254,709</u>	<u>134,697</u>	<u>(100,582)</u>	<u>288,824</u>

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2024 (continued)

12 Analysis of net assets between funds

	Unrestricted	Total funds
	General	2024
	£	£
Current assets	299,229	299,229
Current liabilities	<u>(7,697)</u>	<u>(7,697)</u>
Total net assets	<u>291,532</u>	<u>291,532</u>
	Unrestricted	Total funds
	General	2023
	£	£
Current assets	296,134	296,134
Current liabilities	<u>(7,310)</u>	<u>(7,310)</u>
Total net assets	<u>288,824</u>	<u>288,824</u>

Action Kidney Cancer

Detailed Statement of Financial Activities for the Year Ended 31 October 2024

	Total 2024 £	Total 2023 £
Income and Endowments from:		
Donations and legacies (analysed below)	82,820	104,633
Investment income (analysed below)	65	-
Other income (analysed below)	<u>32,656</u>	<u>30,064</u>
Total income	<u>115,541</u>	<u>134,697</u>
Expenditure on:		
Charitable activities (analysed below)	<u>(112,833)</u>	<u>(100,582)</u>
Total expenditure	<u>(112,833)</u>	<u>(100,582)</u>
Net income	<u>2,708</u>	<u>34,115</u>
Net movement in funds	2,708	34,115
Reconciliation of funds		
Total funds brought forward	<u>288,824</u>	<u>254,709</u>
Total funds carried forward	<u><u>291,532</u></u>	<u><u>288,824</u></u>

Action Kidney Cancer

Detailed Statement of Financial Activities for the Year Ended 31 October 2024 (continued)

	Total 2024 £	Total 2023 £
<i>Donations and legacies</i>		
Appeals and donations	41,610	29,633
Grants - other agencies	5,000	75,000
Restricted income	36,210	-
	<u>82,820</u>	<u>104,633</u>
<i>Investment income</i>		
Bank interest receivable	65	-
	<u>65</u>	<u>-</u>
<i>Other income</i>		
Advocacy fees	32,656	30,064
	<u>32,656</u>	<u>30,064</u>
<i>Charitable activities</i>		
Rent	(1,035)	(660)
Insurance	(174)	12
Advocacy and medical relations	(30,033)	(28,314)
Telephone and fax	(166)	(168)
Communications	(11,242)	(11,185)
Office and administration	(7,351)	(8,657)
Website and maintenance	(7,663)	(7,744)
Printing, postage and stationery	(26)	-
Patient Support	(15,625)	(14,750)
Sundry expenses	(25)	(240)
Project management	(1,908)	(7,838)
Travel and subsistence	(2,633)	(1,087)
Marketing Material	(499)	(23)
Fundraising costs	(12,340)	(11,970)
Patient Days	4,711	-
Events	(2,536)	-
Charity meeting	-	(5,071)
Accountancy fees	(100)	(100)
Legal and professional fees	(1,567)	(1,180)
Restricted expenditure	(20,953)	-
All Giving platform charges	(1,669)	(1,364)
Depreciation of office equipment	-	(243)
Office and administration	1	-
	<u>(112,833)</u>	<u>(100,582)</u>

This page does not form part of the statutory financial statements.